Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry


ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Research Article

In Vitro Demonstration of Drug-Reagent Interactions Among Commonly Used Parenteral Drugs in Cardiology

Author(s): Ataman Gönel*, Mustafa B. Tascanov, Nihayet Bayraktar, Ismail Koyuncu, Veysel Agan, Mehmet Enes and Ahmet Guzelcicek

Volume 19 , Issue 1 , 2021

Published on: 26 February, 2020

Page: [43 - 49] Pages: 7

DOI: 10.2174/1871525718666200226115235

Price: $65


Background: Drug-drug interactions are undesirable, as they reduce drug bioavailability. Drug-reagent interactions in biochemical tests may directly affect the accuracy of test results.

Objective: The aim of the present study was to investigate the impact of drug-reagent interactions of drugs used in cardiology on different cardiac markers (troponin I, Nt-proBNP, CK-MB mass, CK, AST, and LDH) and the D-dimer test.

Methods: Eleven drugs (enoxaparin, tirofiban hydrochloride monohydrate, diltiazem, glyceryl trinitrate, metoprolol, epinephrine, heparin sodium, atropine sodium, furosemide, norepinephrine tartrate, and amiodarone HCl) were tested in an interference study. The interference protocol was applied to the control material of troponin I, CK-MB mass, Nt-proBNP, CK, AST, LDH tests with 11 different drugs and performed with analyzers. Cardiac Markers Plus Control (Bio-Rad, Irvine, CA, USA; Lot: 23662) materials were used to assess the impact of drug-reagent interactions on the accuracy of tests of cardiac markers based on immunoassay methods. The bias rate, defined as the extent of deviation from the target value (bias %), in the interference study was calculated in each test.

Results: For all 11 drugs, positive interference in the range of 43.58% to 130.06% occurred in the CK-MB mass test, whereas positive interference in the range of 11.98% to 107.44% occurred in the troponin I test. All the drugs, except enoxaparin sodium, led to negative interference in the range of - 84.21 to -29.6% in the Nt-proBNP test. In the D-dimer test, amiodarone HCl and diltiazem caused interference (122.87% and 28.08%, respectively). The percentage of interference caused by the other drugs ranged from -1.27% to 11.44%. Minimal deviations in the target values (between -3.31% and 3.86%) were observed in the CK, AST, and LDH tests measured using spectrophotometric methods.

Conclusion: Parenteral drugs used in cardiology can significantly interfere with troponin I, CK-MB mass, Nt-proBNP, and D-dimer tests in the analytical phase because of drug-reagent interactions. Minimal deviations in the CK, AST, and LDH tests were observed using spectrophotometric methods. Thus, changes in test results may be due to drug interference rather than the treatment itself. Clinicians should consider the possibility of drug interference in cases of doubtful cardiac test results that do not comply with the diagnosis.

Keywords: Cardiac drugs, CK-MB mass, interference, markers, Nt-proBNP, troponin I.

Graphical Abstract
Vrettos, I.; Voukelatou, P.; Katsoras, A.; Theotoka, D.; Kalliakmanis, A. Diseases linked to polypharmacy in elderly patients. Curr. Gerontol. Geriatr. Res., 2017.
Tascanov, M.B.; Gönel, A. How do contrast agents affect cardiac markers and coagulation tests? experimental study. Comb. Chem. High Throughput Screen., 2019, 22(5), 355-360.
[] [PMID: 31161978]
Berner, E.S.; Graber, M.L. Overconfidence as a cause of diagnostic error in medicine. Am. J. Med., 2008, 121(5), S2-S23.
[] [PMID: 18440350]
Plebani, M. Exploring the iceberg of errors in laboratory medicine. Clin. Chim. Acta, 2009, 404(1), 16-23.
[] [PMID: 19302995]
Trambas, C.; Lu, Z.; Yen, T.; Sikaris, K. Characterization of the scope and magnitude of biotin interference in susceptible Roche elecsys competitive and sandwich immunoassays. Ann. Clin. Biochem., 2018, 55(2), 205-215.
[] [PMID: 28875734]
Willeman, T.; Casez, O.; Faure, P.; Gauchez, A.S. Evaluation of biotin interference on immunoassays: New data for troponin I, digoxin, NT-Pro-BNP, and progesterone. Clin. Chem. Lab. Med., 2017, 55(10), e226-e229.
[] [PMID: 28222017]
Dasgupta, A. Biotin and Other Interferences in Immunoassays: A Concise Guide; Elsevier, 2019.
Tate, J.; Ward, G. Interferences in immunoassay. Clin. Biochem. Rev., 2004, 25(2), 105-120.
[PMID: 18458713]
Wild, D. The immunoassay handbook: Theory and applications of ligand binding, ELISA and related techniques; Newnes, 2013.
Kricka, L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem., 1999, 45(7), 942-956.
[PMID: 10388468]
Martínez González, J.; Monreal, M.; Ayani Almagia, I.; Llaudó Garín, J.; Ochoa Díaz de Monasterioguren, L.; Gutierro Adúriz, I. Bioequivalence of a biosimilar enoxaparin sodium to Clexane after single 100 mg subcutaneous dose: Results of a randomized, double-blind, crossover study in healthy volunteers. Drug Des. Devel. Ther., 2018, 12, 575-582.
[] [PMID: 29593380]
Peela, J.R.; Jarari, A.M.; Hai, A.; Rawal, A.K.; Kolla, S.D.; Sreekumar, S.; Khurana, L.; Sidhanathi, N.R. Cardiac Biomarkers: The Troponins and CK-MB. Ibnosina J. Med. Biomed. Sci., 2010, 2(5)
Peacock, W.F.; Baumann, B.M.; Bruton, D.; Davis, T.E.; Handy, B.; Jones, C.W.; Hollander, J.E.; Limkakeng, A.T.; Mehrotra, A.; Than, M.; Ziegler, A.; Dinkel, C. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. JAMA Cardiol., 2018, 3(2), 104-111.
[] [PMID: 29238804]
Apple, F.S.; Murakami, M.M. Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. Clin. Chem., 2005, 51(2), 460-463.
[] [PMID: 15563477]
Katzung, B.G.; Trevor, A.J. Basic & clinical pharmacology; McGraw-Hill Education New York, 2015.
Zheng, J.; Xiang, X.; Li, H.; Xiao, B.; Yuan, T.; Gong, X.; Yao, S. Comprehensive analysis clinical effectiveness of Tirofiban for patients with non-ST-elevation acute coronary syndrome, 2018.
Loria, V.; Leo, M.; Biasillo, G.; Dato, I.; Biasucci, L.M. Biomarkers in acute coronary syndrome. Biomark. Insight, 2008, 3, S588.
White, G.H.; Tideman, P.A. Heterophilic antibody interference with CARDIAC T quantitative rapid assay. Clin. Chem., 2002, 48(1), 201-203.
[] [PMID: 11751561]
Wu, A.H.; Smith, A.; Christenson, R.H.; Murakami, M.M.; Apple, F.S. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin. Chim. Acta, 2004, 346(2), 211-219.
[] [PMID: 15256323]
Avouac, J.; Meune, C.; Chenevier-Gobeaux, C.; Dieudé, P.; Borderie, D.; Lefevre, G.; Kahan, A.; Allanore, Y. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J. Rheumatol., 2014, 41(2), 248-255.
[] [PMID: 24334650]
Covinsky, M.; Laterza, O.; Pfeifer, J.D.; Farkas-Szallasi, T.; Scott, M.G. An IgM λ antibody to Escherichia coli produces false-positive results in multiple immunometric assays. Clin. Chem., 2000, 46(8 Pt 1), 1157-1161.
[] [PMID: 10926897]
Bais, R. The effect of sample hemolysis on cardiac troponin I and T assays. Clin. Chem., 2010, 56(8), 1357-1359.
[] [PMID: 20525763]
Eriksson, S.; Halenius, H.; Pulkki, K.; Hellman, J.; Pettersson, K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin. Chem., 2005, 51(5), 839-847.
[] [PMID: 15718489]
Murthy, J.N.; Davis, D.L.; Yatscoff, R.W.; Soldin, S.J. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin. Biochem., 1998, 31(8), 613-617.
[] [PMID: 9876892]
Murthy, J.N.; Yatscoff, R.W.; Soldin, S.J. Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin. Biochem., 1998, 31(3), 159-163.
[] [PMID: 9629489]
Ska, J.; Owczarek, J.; Orszulak-Michalak, D. The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study. Acta. Pol. Pharm., 2006, 1, 5.
Ismail, A.A.; Walker, P.L.; Cawood, M.L.; Barth, J.H. Interference in immunoassay is an underestimated problem. Ann. Clin. Biochem., 2002, 39(Pt 4), 366-373.
[] [PMID: 12117440]
Bildirisi, Y. Klinik biyokimya laboratuvarında ölçüm belirsizliği: Pratik uygulama. Turkish J. Biochem., 2011, 36(4), 362-366.
Bal, C.; Serdar, M.A.; Güngör, O.T.; Çelik, H.T.; Abuşoğlu, S.; Uğuz, N.; Erden, G.; Yıldırımkaya, M. Biyokimya parametrelerinin ölçüm belirsizliğinin hesaplanması. Turk. J. Biochem., 2014, 39(4), 538-543.
Fuentes-Arderiu, X. Uncertainty of measurement in clinical laboratory sciences. Clin. Chem., 2000, 46(9), 1437-1438.
[] [PMID: 10973882]
White, G.H.; Farrance, I. AACB Uncertainty of Measurement Working Group. Uncertainty of measurement in quantitative medical testing: A laboratory implementation guide. Clin. Biochem. Rev., 2004, 25(4), S1-S24.
[PMID: 18650962]
Ayyildiz, S.N. Research Article The importance of measuring the uncertainty of second-generation total testosterone analysis. Int. J. Med. Biochem., 2018, 1(1), 34-39.
García-González, E.; Aramendía, M.; Álvarez-Ballano, D.; Trincado, P.; Rello, L. Serum sample containing endogenous antibodies interfering with multiple hormone immunoassays. Laboratory strategies to detect interference. Pract. Labor. Med., 2016, 4, 1-10.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy